|BIBCL -- India Stock|| |
INR 16.00 0.20 1.23%
Assuming 30 trading days horizon, and your above average risk tolerance our recommendation regarding Bharat Immunologicals Biologicals Corp Ltd is 'Hold'
. Macroaxis provides Bharat Immunologicals buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding BIBCL positions. The advice algorithm takes into account all of Bharat Immunologicals available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from BIBCL buy-and-hold prospective. Check also Bharat Immunologicals Analyst Recommendation
to compare Macroaxis Buy or Sell Recommendation with current analyst consensus.
For the selected time horizon Bharat Immunologicals Biologicals Corp Ltd has a risk adjusted performance of 0.01, jensen alpha of 0.0, total risk alpha of 0.0, sortino ratio of 0.0 and treynor ratio of 0.0
This buy or sell advice tool can be used to cross verify current analyst consensus
on Bharat Immunologicals and to analyze the company potential to grow in the current economic cycle. To make sure Bharat Immunologicals is not overpriced, please confirm all Bharat Immunologicals fundamentals including its Current Valuation
, Gross Profit
, Debt to Equity
, as well as the relationship
between Price to Book
and Cash and Equivalents
Returns Distribution Density
|Mean Return||0.54||Value At Risk||4.4|
|Potential Upside||2.24||Standard Deviation||2.93|
Bharat Immunologicals Greeks
Bharat Immunologicals Volatility Alert
Bharat Immunologicals Biologicals Corp Ltd exhibits very low volatility with skewness of -1.7 and kurtosis of 5.2. However, we advise investors to further study Bharat Immunologicals Biologicals Corp Ltd technical indicators to make sure all market info is available and is reliable.
Bharat Immunologicals Fundamental Vs Peers
|Bharat Immunologicals generates negative expected return over the last 30 days|
|The company reported revenue of 347.99 M. Net Loss for the year was (51.73 M) with profit before overhead, payroll, taxes, and interest of 48.93 M. |
|Latest headline from in.reuters.com: ICRA ratings for Indian debt instruments-Jul 27|